GMAB

Genmab A/S is a Danish biotechnology company specializing in the creation and development of antibody therapeutics for cancer treatment. The company has developed a proprietary technology platform for generating differentiated antibody drug candidates with enhanced therapeutic properties. Genmab's marketed products include Darzalex (daratumumab) for multiple myeloma, developed in partnership with Johnson & Johnson, which has become a blockbuster therapy. The company also markets Tepezza (teprotumumab) for thyroid eye disease and Tivdak (tisotumab vedotin) for cervical cancer. Genmab maintains strategic collaborations with major pharmaceutical companies including AbbVie, Johnson & Johnson, and Novartis for the development and commercialization of its antibody pipeline. The company's research focuses on next-generation antibody formats including bispecific antibodies and antibody-drug conjugates. Genmab has established itself as a leader in antibody innovation with multiple commercial products and a robust clinical pipeline.